Expression profiling identifies microRNA signature in pancreatic cancer

By E. J. Lee, Yuriy Gusev, Jinmai Jiang, G. Nuovo, M. Lerner, W. Frankel, D. Morgan, R. Postier, D. Brackett, Thomas D. Schmittgen. International Journal of Cancer, 2006

966 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6040c2009004d808993ea6d892b808a2403e2a72

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation (2007, background): “…three papers reporting the differential expression of miRNAs in primary glioblastomas, papillary thyroid carci- nomas and pancreas tumors, describe the upregulation of miR-221 as part of a cancer signature (Ciafre et al, 2005; He et al, 2005a; Pallante et al, 2006; Lee et al, 2007).”
miR-155 gene: a typical multifunctional microRNA. (2009, background): “Two independent studies detected a 10-14 fold up regulation of miR-155 in PDAC with respect to normal pancreatic tissue [54, 55].”
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. (2008, background): “Subsequently, miRNA deregulation was detected in other human malignancies, including breast carcinoma (4, 5), primary glioblastoma (6, 7), lung cancer (8), papillary thyroid carcinoma (9), colon carcinoma (10), and pancreatic tumors (11, 12).”
Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. (2008, background): “Studies have shown that miR-155 accumulates in chronic lymphocytic leukemia (34), lymphomas (30,35), breast cancer, and pancreatic cancer (36, 37 ).”
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death (2008, background): “overexpressed in pancreatic cancer (Lee et al., 2007; Szafranska et al., 2007).”
OncomiRs: the discovery and progress of microRNAs in cancers (2007, background): “Aberrant miRNA expression offered new clues to pancreatic tumorigenesis and might provide diagnostic biomarkers for pancreatic cancer [ 49 ].”
Lost in translation: an assessment and perspective for computational microRNA target identification (2009, background): “Analyzing their expression, several miRNA signatures have already been successfully associated with human cancers (Calin and Croce, 2006) such as leukemias (Calin and Croce, 2007; Landais et al., 2007), thyroid carcinomas (He et al., 2005), breast (Iorio et al., 2005), lung (Yanaihara et al., 2006) ”
microRNAs in cancer (2013, background): “The miR-155 gene is overexpressed in several solid tumors—for example, in breast cancer (38, 77), colon cancer (38), cervical cancer (128), pancreatic ductal adenocarcinoma (129), thyroid carcinoma (130), and lung cancer (131)—where it is considered a marker of poor prognosis.”